EGFR and lung carcinoma: PLGA NPs (~ 270 nm with a surface charge of ~ 42 mV) loaded with brigatinib, an epidermal growth factor receptor (EGFR) inhibitor, showed the IC50 of 5.25 μg/ml against lung carcinoma cell line A549 [36].